BRUKINSA
Drug
BeiGene, Ltd.
Total Payments
$261.1M
Transactions
44,915
Doctors
8,301
Companies
5
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $57.9M | 13,642 | 4,652 |
| 2023 | $60.4M | 12,625 | 4,284 |
| 2022 | $49.5M | 8,348 | 3,027 |
| 2021 | $58.0M | 6,720 | 2,176 |
| 2020 | $35.4M | 3,580 | 1,054 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $251.7M | 12,142 | 96.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $5.4M | 1,749 | 2.1% |
| Consulting Fee | $2.1M | 1,288 | 0.8% |
| Food and Beverage | $990,900 | 27,903 | 0.4% |
| Travel and Lodging | $641,301 | 1,582 | 0.2% |
| Space rental or facility fees (teaching hospital only) | $248,900 | 30 | 0.1% |
| Education | $5,847 | 221 | 0.0% |
Payments by Type
Research
$251.7M
12,142 transactions
General
$9.4M
32,773 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | BeiGene, Ltd. | $43.9M | 0 |
| A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Intolerant of Prior Treatment with Ibrutinib | BeiGene, Ltd. | $42.2M | 0 |
| An International, Phase 3, Open-Label, Randomized Study of BGB-3111 Compared With Bendamustine Plus Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL) | BeiGene, Ltd. | $23.1M | 0 |
| An Open-label, Multi-center, Monotherapy, Long-term Extension Study of Zanubrutinib (BGB-3111) in Patients with B-cell Malignancies | BeiGene, Ltd. | $18.7M | 0 |
| A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients With Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment With Ibrutinib and/or Acalabrutinib | BeiGene, Ltd. | $17.4M | 0 |
| An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies | BeiGene, Ltd. | $16.4M | 0 |
| A Phase 1/1b Open-Label Dose Escalation and Expansion Study of Bcl-2 Inhibitor BGB-11417 in Patients with Mature B-Cell Malignancies | BeiGene, Ltd. | $12.5M | 0 |
| A Phase 3 Randomized, Open-Label, Multicenter Study Comparing Zanubrutinib (BGB-3111) Plus Rituximab Versus Bendamustine Plus Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation | BeiGene, Ltd. | $10.4M | 0 |
| A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib | BeiGene, Ltd. | $10.1M | 0 |
| A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia | BeiGene, Ltd. | $9.1M | 0 |
| A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Clinical Study Comparing the Efficacy and Safety of Tislelizumab (BGB-A317) Plus Platinum and Fluoropyrimidine Versus Placebo Plus Platinum and Fluoropyrimidine as First-Line Treatment in Patients Wi | BeiGene, Ltd. | $9.0M | 0 |
| An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients with B-cell Malignancies | BeiGene, Ltd. | $7.9M | 0 |
| Phase 3 Randomized, Open -Label, Multicenter Study Comparing Zanubrutinib (BGB-3111) plus Rituximab Versus Bendamustine plus Rituximab in Patients with Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation | BeiGene, Ltd. | $4.7M | 0 |
| A Phase 3, Randomized, Open-Label, Multicenter Study Comparing the Efficacy and Safety of the Bruton's Tyrosine Kinase (BTK) Inhibitors BGB-3111 and Ibrutinib in Subjects With Waldenstrom's Macroglobulinemia (WM) | BeiGene, Ltd. | $2.9M | 5 |
| A Phase 2, Randomized, Double Blind, Placebo-Controlled Study of Zanubrutinib Treatment in Patients Hospitalized for COVID 19 Infection and Pulmonary Distress | BeiGene, Ltd. | $1.9M | 0 |
| A Single-Arm, Expanded Access Study of Zanubrutinib (BGB-3111) in Patients with B-cell Malignancies | BeiGene, Ltd. | $1.8M | 0 |
| A Single-dose, Open-label, Randomized, Replicate Crossover Study in Healthy Adult Subjects to Assess the Bioequivalence of a Zanubrutinib Tablet Compared to Zanubrutinib Capsules | BeiGene Switzerland GmbH | $1.8M | 0 |
| (BOVEN) Phase 2 study of Zanubrutinib, Obinutuzumab, and Venetoclax in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL). | BeiGene USA, Inc. | $1.7M | 0 |
| A Phase 3 Randomized, Open-Label, Multicenter Study of Zanubrutinib (BGB 3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | BeiGene, Ltd. | $1.4M | 0 |
| A Single-Dose, Open-Label, Randomized, Crossover Study in Healthy Adult Subjects to Assess the Relative Bioavailability of a Zanubrutinib 160 mg Tablet Compared to two 80 mg Capsules and to Evaluate the Effects of Food on the Pharmacokinetics of the Zanub | BeiGene, Ltd. | $1.0M | 0 |
Top Doctors Receiving Payments for BRUKINSA — Page 4
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , M.D | Hematology & Oncology | Pensacola, FL | $30,263 | 24 |
| , M.D | Hematology | Fort Myers, FL | $29,950 | 33 |
| , MD | Internal Medicine | Columbus, OH | $28,288 | 25 |
| , MD, PHD | Specialist | Boston, MA | $27,714 | 13 |
| , M.D | Hematology & Oncology | Memphis, TN | $27,506 | 29 |
| , M.D | Hematology & Oncology | San Diego, CA | $26,533 | 20 |
| , M.D | Hematology & Oncology | New Hyde Park, NY | $26,484 | 22 |
| , M.D, PHD | Hematology & Oncology | Morristown, NJ | $26,245 | 33 |
| , M.D | Medical Oncology | Orange, CA | $26,120 | 24 |
| , M.D | Hematology & Oncology | Birmingham, AL | $24,861 | 16 |
| , M.D | Hematology & Oncology | Sacramento, CA | $23,976 | 15 |
| , MD | Internal Medicine | Orange, CA | $23,420 | 22 |
| , NP | Nurse Practitioner | Milwaukee, WI | $22,838 | 40 |
| , MD | Medical Oncology | New York, NY | $22,093 | 14 |
| , APRN | Nurse Practitioner | Ellington, CT | $21,708 | 35 |
| , M.D | Hematology & Oncology | Seattle, WA | $21,695 | 27 |
| , MD | Hematology & Oncology | Orlando, FL | $20,614 | 10 |
| , MD | Medical Oncology | Saint Louis, MO | $20,603 | 16 |
| , M.D., M.S | Internal Medicine | Los Angeles, CA | $20,365 | 17 |
| , MD | Internal Medicine | Wichita, KS | $20,184 | 30 |
| , M.D. , M.P.H | Hematology & Oncology | Albany, NY | $19,727 | 15 |
| , D.O | Internal Medicine | Tulsa, OK | $19,382 | 18 |
| , M.D | Hematology & Oncology | Atlanta, GA | $19,142 | 5 |
| , MD PHD | Internal Medicine | Boston, MA | $19,100 | 9 |
| , M.D | Internal Medicine | Duarte, CA | $18,378 | 14 |
Ad
Manufacturing Companies
- BeiGene, Ltd. $240.5M
- BeiGene USA, Inc. $14.7M
- BeiGene Switzerland GmbH $5.1M
- BeiGene AUS Pty Ltd $522,178
- BeiGene (Suzhou) Co., Ltd. $288,913
Product Information
- Type Drug
- Total Payments $261.1M
- Total Doctors 8,301
- Transactions 44,915
About BRUKINSA
BRUKINSA is a drug associated with $261.1M in payments to 8,301 healthcare providers, recorded across 44,915 transactions in the CMS Open Payments database. The primary manufacturer is BeiGene, Ltd..
Payment data is available from 2020 to 2024. In 2024, $57.9M was paid across 13,642 transactions to 4,652 doctors.
The most common payment nature for BRUKINSA is "Unspecified" ($251.7M, 96.4% of total).
BRUKINSA is associated with 20 research studies, including "A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma" ($43.9M).